The research is still early , but the mechanistic rationale is compelling
However, the FDA has not yet approved Semaglutide as a direct treatment for chronic kidney disease, though it is approved for diabetes and weight loss
Together, these barriers can maintain the balance between pro- and anti-inflammatory factors
Both semaglutide and tirzepatide are well-known for their effects on weight loss and blood sugar control, but our study suggests they may also offer substantial benefits to patients with obesity and Type 2 diabetes by reducing adverse heart failure outcomes. By analyzing real-world data from over 90,000 HFpEF patients with obesity and Type 2 diabetes, researchers from MGB demonstrated that GLP-1 medications may significantly reduce the risk of hospitalization due to heart failure and all-cause mortality
The complexity of its tri-agonist mechanism demands the highest possible standard of purity and identity verification
Metformin inhibits inflammation and bone destruction in collagen-induced arthritis in rats
